The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Open accessAbstract
Background & aims Some patients with nonalcoholic fatty liver disease (NAFLD) develop liver-related complications and have higher mortality than other patients with NAFLD. We determined the accuracy of simple, noninvasive scoring systems in identification of patients at increased risk for liver-related complications or death.Methods We performed a retrospective, international, multicenter cohort study of 320 patients diagnosed with NAFLD, based on liver biopsy analysis through 2002 and followed through 2011. Patients were assigned to mild-, intermediate-, or high-risk groups based on cutoff values for 2 of the following: NAFLD fibrosis score, aspartate aminotransferase/platelet ratio index, FIB-4 score, and BARD score. Outcomes included liver-related complications and death or liver transplantation. We used multivariate Cox proportional hazard regression analysis to adjust for relevant variables and calculate adjusted hazard ratios (aHRs).Results During a median follow-up period of 104.8 months (range, 3-317 months), 14% of patients developed liver-related events and 13% died or underwent liver transplantation. The aHRs for liver-related events in the intermediate-risk and high-risk groups, compared with the low-risk group, were 7.7 (95% confidence interval [CI]: 1.4-42.7) and 34.2 (95% CI: 6.5-180.1), respectively, based on NAFLD fibrosis score; 8.8 (95% CI: 1.1-67.3) and 20.9 (95% CI: 2.6-165.3) based on the aspartate aminotransferase/platelet ratio index; and 6.2 (95% CI: 1.4-27.2) and 6.6 (95% CI: 1.4-31.1) based on the BARD score. The aHRs for death or liver transplantation in the intermediate-risk and high-risk groups compared with the low-risk group were 4.2 (95% CI: 1.3-13.8) and 9.8 (95% CI: 2.7-35.3), respectively, based on the NAFLD fibrosis scores. Based on aspartate aminotransferase/platelet ratio index and FIB-4 score, only the high-risk group had a greater risk of death or liver transplantation (aHR = 3.1; 95% CI: 1.1-8.4 and aHR = 6.6; 95% CI: 2.3-20.4, respectively).Conclusions Simple noninvasive scoring systems help identify patients with NAFLD who are at increased risk for liver-related complications or death. NAFLD fibrosis score appears to be the best indicator of patients at risk, based on HRs. The results of this study require external validation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Six retrospective cohort studies on individuals with biopsy-proven MASLD showed that NFS and FIB-4 predict the occurrence of liver-related events (AUROCs from 0.72 to 0.86) and overall mortality (AUROCs from 0.67 to 0.82), 176,177 with a similar or lower accuracy compared to histology.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,135
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,255
Obesity and Cardiovascular Disease
Lavie, C. J., Milani, R. V., & Ventura, H. O. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.068 · Cited by 2,326
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
de Franchis, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.004 · Cited by 2,291
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Flagged first, then by citations
1 of the 32 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Gedaly, 2012, Rising incidence of nonalcoholic steatoheptitis among patients transplanted for hepatocellular carcinoma in the United States, Hepatology, 56, 40A
Cited by
Sorted by citations
Items 301–400 of 501
Katsuyama, H., Hakoshima, M., Kaji, E., Mino, M., Kakazu, E., Iida, S., Adachi, H., Kanto, T., & Yanai, H. (2024) · Biomedicines · doi:10.3390/biomedicines12051001 · Cited by 13
Amoroso, M., Augustín, S., Moosmang, S., & Gashaw, I. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02448-2 · Cited by 15
El‐Sehrawy, A. A. M. A., Jafari, M. T., Zwamel, A. H., Rashidian, P., Ballal, S., Kalia, R., Nanda, A., Maharana, L., Javankiani, S., Hashemi, M., et al. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-00926-y · Cited by 13
Mikolašević, I., Orlić, L., Milić, S., Lukenda, V., Rački, S., Štimac, D., Avdović, E., & Zaputović, L. (2014) · Wiener klinische Wochenschrift · doi:10.1007/s00508-014-0538-0 · Cited by 13
Miller, M. H., Fraser, A. G., Leggett, G., MacGilchrist, A., Gibson, G., Orr, J. G., Forrest, E. H., Dow, E., Bartlett, W. A., Weatherburn, C., et al. (2018) · Frontline Gastroenterology · doi:10.1136/flgastro-2017-100909 · Cited by 14
George, E. S., Roberts, S. K., Nicoll, A., Reddy, A. J., Paris, T., Itsiopoulos, C., & Tierney, A. C. (2018) · Internal Medicine Journal · doi:10.1111/imj.13973 · Cited by 12
Zheng, J., Chen, S., Cai, Y., Lin, S., Ke, S., & Liu, L. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820947550 · Cited by 12
Yi, M., Peng, W. J., Teng, F., Kong, Q., & Chen, Z. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002462 · Cited by 12
Lombardi, R., Lever, R. A., Smith, C. J., Marshall, N., Rodger, A. J., Bhagani, S. R., & Tsochatzis, E. A. (2016) · Journal of Hepatology · doi:10.1016/s0168-8278(16)01433-1 · Cited by 12
Patel, P. J., Connoley, D. J., Rhodes, F., Srivastava, A., & Rosenberg, W. M. (2019) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563219879962 · Cited by 12
Wood, S. M., Won, S., Hsieh, H.-C., Lalani, T., Kronmann, K., Maves, R. C., Utz, G. C., Schofield, C. M., Colombo, R. E., Okulicz, J. F., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab076 · Cited by 12
Noninvasive Algorithms for the Case Finding of “At-Risk” Patients with NAFLD
Castéra, L., & Boursier, J. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1751081 · Cited by 12
Fukuda, K., Seki, Y., Ichihi, M., Okada, T., Hirata, A., Kogita, S., Sawai, Y., Igura, T., Tsugawa, M., & Imai, Y. (2015) · Journal of Medical Ultrasonics · doi:10.1007/s10396-015-0615-7 · Cited by 12
Solomon, A., Cipăian, C. R., Negrea, M. O., Boicean, A., Mihăilă, R. G., Beca, C., Popa, M. L., Grama, S. M., Teodoru, M., & Neamtu, B. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175657 · Cited by 11
Nishikawa, H., Osaki, Y., Komekado, H., Sakamoto, A., Saito, S., Nishijima, N., Nasu, A., Arimoto, A., Kita, R., & Kimura, T. (2014) · Oncology Reports · doi:10.3892/or.2014.3573 · Cited by 11
Patel, M., Puangsricharoen, P., Arshad, H. M. S., Garrison, S., Techasatian, W., Ghabril, M., Sandrasegaran, K., Liangpunsakul, S., & Tann, M. A. (2019) · Abdominal Radiology · doi:10.1007/s00261-019-02145-6 · Cited by 11
Sakamoto, Y., Yoshio, S., Doi, H., Kawai, H., Shimagaki, T., Mori, T., Matsuda, M., Aoki, Y., Osawa, Y., Yoshida, Y., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13464 · Cited by 11
Billeter, A., Wloka, S., Behnisch, R., Albrecht, T., Roessler, S., Goeppert, B., Mueller, S., Nickel, F., & Müller, B. (2021) · Obesity Facts · doi:10.1159/000517383 · Cited by 9
Ishiba, H., Fujii, H., Kamada, Y., Sumida, Y., Takahashi, K., Seko, Y., Toyoda, H., Hayashi, H., Yamaguchi, K., Iwaki, M., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000563 · Cited by 10
Epidemiological Trends in NASH as a Cause for Liver Transplant
Siow, W., van der Poorten, D., & George, J. (2016) · Current Hepatology Reports · doi:10.1007/s11901-016-0294-x · Cited by 10
Gentili, A., Daviddi, G., VUONO, S. D., Ricci, M. A., Filippo, F. D., Alaeddin, A., Mannarino, M. R., Boni, M., Vaudo, G., & Lupattelli, G. (2016) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.04.004 · Cited by 10
Grecian, S. M., McLachlan, S., Fallowfield, J. A., Hayes, P. C., Guha, I. N., Morling, J. R., Glancy, S., Williamson, R. M., Reynolds, R. M., Frier, B. M., et al. (2021) · Obesity Science & Practice · doi:10.1002/osp4.484 · Cited by 10
Coutinho, A., Reddy, N., Chatterjee, A., & Khan, M. I. (2021) · Global Medical Genetics · doi:10.1055/s-0041-1728690 · Cited by 10
Kim, H. M., & Lee, Y. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1087 · Cited by 10
Peng, J., Liu, M., Jin, J., Cao, Y., Guo, Y., Wu, N., Zhu, C., Dong, Q., Sun, J., Xu, R., et al. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-021-01610-w · Cited by 10
Non-Alcoholic Fatty Liver Disease: Diagnosis and Investigation
Nascimbeni, F., Loria, P., & Ratziu, V. (2014) · Digestive Diseases · doi:10.1159/000360510 · Cited by 10
Hígado graso no alcohólico. Documento de posicionamiento de la Societat Catalana de Digestologia
Caballería, L., Saló, J., Berzigotti, A., Planas, R., Vila, M. C., Huertas, C., Torres, M., Torán‐Monserrat, P., & Caballería, J. (2014) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2014.03.005 · Cited by 11
Antioxidant Lifestyle, Co-Morbidities and Quality of Life Empowerment Concerning Liver Fibrosis
Martínez‐Urbistondo, D., Carrero, R. S. D. V., Argemí, J., Daimiel, L., Ramos-López, O., San-Cristóbal, R., Villares, P., & Martínez, J. A. (2020) · Antioxidants · doi:10.3390/antiox9111125 · Cited by 9
Broussier, T., Lannes, A., Zuberbuhler, F., Oberti, F., Fouchard, I., Hunault, G., Calès, P., & Boursier, J. (2019) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2019.07.010 · Cited by 9
Xin, Z., Liu, S., Niu, J., Xu, M., Wang, T., Lu, J., Chen, Y., Wang, W., Ning, G., Bi, Y., et al. (2020) · Liver International · doi:10.1111/liv.14649 · Cited by 9
Gabriel-Medina, P., Ferrer, R., Ciudin, A., Augustín, S., Rivera‐Esteban, J., Pericàs, J. M., Selva, D. M., & Rodríguez‐Frias, F. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03441-2 · Cited by 11
Luckhoff, H. K. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i9.1192 · Cited by 9
NAFLD and Cardiovascular Disease: Can the Real Association Be Determined?
Trivedi, I., & Rinella, M. E. (2014) · Current Hepatology Reports · doi:10.1007/s11901-014-0231-9 · Cited by 9
Morling, J. R., & Guha, I. N. (2016) · Clinical Liver Disease · doi:10.1002/cld.555 · Cited by 9
Bhat, M., Rollet‐Kurhajec, K. C., Bhat, A., Farag, A., Deschênes, M., Wong, P. Y. N., Ghali, P., & Sebastiani, G. (2017) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2017/4381864 · Cited by 9
Cheung, K. S., Seto, W., Fung, J., Mak, L., Lai, C., & Yuen, M. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i44.7863 · Cited by 9
Oluyede, D. M., Lawal, A. O., Adebimpe, M. O., Olumegbon, L. T., & Elekofehinti, O. O. (2021) · Air Quality Atmosphere & Health · doi:10.1007/s11869-021-00991-2 · Cited by 9
NAFLD Fibrosis Score: Is It Ready for Wider Use in Clinical Practice and for Clinical Trials?
Gawrieh, S., & Chalasani, N. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.025 · Cited by 9
Chimakurthi, C. R., & Rowe, I. A. C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.034 · Cited by 9
Stine, J. G., & Rinella, M. E. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.60 · Cited by 9
Bradley, C. R., Cox, E. F., Palaniyappan, N., Aithal, G. P., Francis, S. T., & Guha, I. N. (2022) · European Radiology Experimental · doi:10.1186/s41747-022-00303-y · Cited by 8
Albhaisi, S. A. M., Sun, J., & Sanyal, A. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1198871 · Cited by 8
Hashim, M. M. A., Khan, M. A. M., Ashraf, M. U., Mohsin, S., Zahoor, K., Niazi, J., Khan, A., Muzaffar, S., Makhdumi, M., Ibad, O. A., et al. (2025) · Cureus · doi:10.7759/cureus.86963 · Cited by 8
Liu, L., Nie, Y., Zhang, Y., Liu, Q., & Zhu, X. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.690825 · Cited by 8
Lee, J., Jo, G., Park, D., Jun, H. J., Bae, J. H., & Shin, M. (2023) · Nutrients · doi:10.3390/nu15061501 · Cited by 8
Noninvasive tests in the evaluation of nonalcoholic fatty liver disease: A review
Tun, K. M., Noureddin, N., & Noureddin, M. (2023) · Clinical Liver Disease · doi:10.1097/cld.0000000000000066 · Cited by 8
Identification and Characterization of Nonalcoholic Fatty Liver Disease
Goldshtein, I., Chodick, G., Kochba, I., Gal, N., Webb, M., & Shibolet, O. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.08.007 · Cited by 8
How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis
Henry, Z. H., & Argo, C. K. (2019) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.09.002 · Cited by 8
Approach to Jaundice and Abnormal Liver Function Test Results
Habib, S., & Shaikh, O. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00007-0 · Cited by 8
Sasaki, R., Miyaaki, H., Narita, S., Fukushima, M., Haraguchi, M., Miuma, S., Hidaka, M., Eguchi, S., Okudaira, S., Abe, K., et al. (2020) · Clinical Transplantation · doi:10.1111/ctr.14175 · Cited by 8
Kosick, H. M.-K., Keyrouz, A., Adeyi, O. A., Sebastiani, G., & Patel, K. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06748-8 · Cited by 8
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers
Terracciani, F., Falcomatà, A., Gallo, P., Picardi, A., & Gentilucci, U. V. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-022-00934-0 · Cited by 9
Lim, G., Chang, Y., Kim, I., Ryu, S., Kwon, R., & Song, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-39154-x · Cited by 8
Epidemiology, Natural History, and Evaluation of Nonalcoholic Fatty Liver Disease
Anstee, Q. M., & Day, C. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00026-4 · Cited by 8
Mendoza, Y. P., Shengir, M., Bosch, J., Sebastiani, G., & Berzigotti, A. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.007 · Cited by 8
Xin, Z., Xu, Y., Li, M., & Zhao, Z. (2020) · Liver International · doi:10.1111/liv.14722 · Cited by 8
TINIAKOS, D. G., Anstee, Q. M., Brunt, E. M., & Burt, A. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00005-3 · Cited by 7
Yan, S., Li, Q., Cao, W., Pei, H., Zhen, S., Wu, Q., Yang, X., & Liang, F. (2025) · Journal of Global Health · doi:10.7189/jogh.15.04003 · Cited by 7
Ishiba, H., Sumida, Y., Kamada, Y., Fujii, H., Iwaki, M., Hayashi, H., Toyoda, H., Oeda, S., Hyogo, H., Kawanaka, M., et al. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16144 · Cited by 7
Arvaniti, P. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0841 · Cited by 7
Marcellin, P., Grotzinger, K. M., Theodore, D., Demuth, D., Manns, M. P., Bañares, R., Pike, J., & Forssén, U. M. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12698 · Cited by 7
Esteatosis hepática: diagnóstico y seguimiento
Caballería, L., Majeed, I., Martínez-Escudé, A., Pillasagua, I. A., & Torán‐Monserrat, P. (2017) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2017.03.001 · Cited by 7
Non-invasive diagnosis of patients with ‘at-risk’ NAFLD : only fibrosis counts?
Geier, A., & Boursier, J. (2020) · Gut · doi:10.1136/gutjnl-2020-320785 · Cited by 7
Association of cardiovascular factors in diabetic patients with non-alcoholic fatty liver disease
Cholongitas, Ε., Tsilingiris, D., Diamantopoulou, P., Mastrogianni, E., Tentolouris, A., Karagiannakis, D. S., Moyssakis, I. E., Papatheodoridis, G., & Tentolouris, N. (2021) · HORMONES · doi:10.1007/s42000-021-00334-x · Cited by 7
Ahmed, H. S., Pedersen, N., Jayanna, M. B., Eyck, P. T., Sánchez, A., & Murali, A. R. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-05725-1 · Cited by 7
Liu, C., Ampuero, J., Pavlides, M., Wong, V. W., Fan, J., Bai, L., Li, H., Wu, D., Zhou, L., Du, L., et al. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15431 · Cited by 7
Possible unrecognised liver injury is associated with mortality in critically ill COVID-19 patients
Romero‐Cristóbal, M., Clemente, A. P. G., Piñeiro, P., Cedeño, J. A., Rayón, L., Río, J. D., Ramos, C. A. M. C., Hernández, D.-A., Cova, M., Caballero, A., et al. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211023410 · Cited by 7
Ashi, S. I. A., Shah, R., Iftikhar, N., Lingvay, I., Kinaan, M., & Mansi, I. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16657 · Cited by 6
Sethasine, S., Teerawongsakul, P., Ruamtawee, W., Treerasoradaj, N., & Navadurong, H. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i37.110829 · Cited by 6
Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease
De, A., Chalasani, N., & Duseja, A. K. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2025.09.003 · Cited by 6
Sebastiani, G., Milić, J., Cervo, A., Saeed, S., Krahn, T., Kablawi, D., Hinai, A. S. A., Lebouché, B., Wong, P. Y. N., Deschênes, M., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020282 · Cited by 6
Advances in fibrosis biomarkers in nonalcoholic fatty liver disease
Ciardullo, S., & Perseghin, G. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2021.09.003 · Cited by 6
Xin, Z., Huang, J., Cao, Q., Wang, J., He, R., Hou, T., Ding, Y., Lu, J., Xu, M., Wang, T., et al. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13314 · Cited by 5
Armandi, A., Caviglia, G. P., Abdulle, A., Rosso, C., Gjini, K., Castelnuovo, G., Guariglia, M., Pérez-Díaz-del-Campo, N., D’Amato, D., Ribaldone, D. G., et al. (2023) · Cancers · doi:10.3390/cancers15061659 · Cited by 6
Debate—a bridge too far: Nonalcoholic fatty liver disease will not exhaust the donor pool
O’Leary, J. G. (2014) · Liver Transplantation · doi:10.1002/lt.23973 · Cited by 6
Yahagi, M., Tsuruta, M., Hasegawa, H., Okabayashi, K., & Kitagawa, Y. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1177 · Cited by 6
How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?
Libman, H., Jiang, Z. G., Tapper, E. B., & Reynolds, E. E. (2019) · Annals of Internal Medicine · doi:10.7326/m19-1125 · Cited by 6
Nishikawa, H., Osaki, Y., Komekado, H., Sakamoto, A., Saito, S., Nishijima, N., Nasu, A., Arimoto, A., Kita, R., & Kimura, T. (2014) · Oncology Reports · doi:10.3892/or.2014.3691 · Cited by 6
Pathogenesis of nonalcoholic fatty liver disease (NAFLD)
Yki‐Järvinen, H. (2015) · doi:10.1002/9781118387658.ch19 · Cited by 6
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
Basheer, M., Naffaa, M. E., & Assy, N. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0045 · Cited by 6
Ferraz‐Amaro, I., Heras-Recuero, E., de Vera-González, A., Delgado, A. G., Romo-Cordero, A., Quevedo-Rodríguez, A., Quevedo-Abeledo, J. C., Largo, R., & González-Gay, M. Á. (2025) · Lara D. Veeken · doi:10.1093/rheumatology/keaf263 · Cited by 5
Extracellular RNAs in Liquid Biopsy: Applications in MASLD and MASH Diagnosis and Monitoring
Raptis, D., Kolli, S. T., Agarwal, S., Komminni, P. K., Bhattarai, P., Hablani, P., Kumar, R., Lohana, P., McIntosh, M. N., Kladas, M., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15182346 · Cited by 5
The association between liver fibrosis scores and chronic kidney disease
Xiong, S., Wang, P., Yin, S., Deng, W., Zhao, Y., Li, W., Li, Z., Zhou, Y., Yu, S., Yang, H., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1046825 · Cited by 5
Chronic Liver Disease – What’s New?
Effandie, E., & Gupte, G. L. (2023) · The Indian Journal of Pediatrics · doi:10.1007/s12098-023-04819-y · Cited by 5
FIB4 score is increased in severe preeclampsia
Özer, S., Güneş, H., & Özer, A. (2023) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2022-0214 · Cited by 5
Ahmed, H. S., Gangasani, N., Jayanna, M. B., Long, M. T., Sánchez, A., & Murali, A. R. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.11.005 · Cited by 5
Ripoll, C. (2015) · Hepatology · doi:10.1002/hep.28273 · Cited by 5
Kao, W., Su, C., Fang, S.-U., Tang, J., Chang, C., & Liu, J. (2018) · Advances in digestive medicine · doi:10.1002/aid2.13102 · Cited by 5
Controlled Attenuation Parameter in Healthy Individuals Aged 8–70 Years
Mjelle, A. B., Mulabecirovic, A., Olafsdottir, E. J., Gilja, O. H., Havre, R. F., & Vesterhus, M. N. (2021) · Ultrasound International Open · doi:10.1055/a-1461-4714 · Cited by 5
Dunn, W., Song, X., Koestler, D. C., Grdinovac, K., Al-Hihi, E. M., Chen, J. L., Taylor, R. M., Wilson, J. M., & Weinman, S. A. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15900 · Cited by 5
Schattenberg, J. M. (2019) · Liver International · doi:10.1111/liv.13999 · Cited by 5
Association between noninvasive hepatic fibrosis indices and heart failure mortality
Aydemir, S., Aydın, S. Ş., Altınkaya, O., Özmen, M., Derman, Ö. F., & Aksakal, E. (2026) · Medicine · doi:10.1097/md.0000000000047301 · Cited by 4
Valoración bioquímica en la enfermedad hepática grasa asociada a la disfunción metabólica
Guerra-Ruiz, A. R., Casals, G., Iruzubieta, P., Lalana, M., Leis, A., López, R. M., Crespo, J., & Morales‐Ruiz, M. (2021) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2020-0062 · Cited by 4
Yasmeen, R., Jabeen, H., Aseena, R., Taneem, K., & Syed, U. (2021) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2021.00959 · Cited by 4
Jacobson, I. M., Wong, V. W., Castéra, L., Anstee, Q. M., Noureddin, M., Cusi, K. J., Harrison, S. A., Bugianesi, E., & Younossi, Z. M. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001780 · Cited by 4
Brindley, J. H., Abeysekera, K. W. M., Hood, G., Jennings, S., Moore, J. W., Hickman, M., & Alazawi, W. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-066493 · Cited by 4
Vaz, K., Kemp, W. W., Majeed, A., Lubel, J. S., Magliano, D. J., Glenister, K., Bourke, L., Simmons, D. S., & Roberts, S. K. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16774 · Cited by 4
Abdominelle Sonografie bei Patienten mit Diabetes mellitus. Teil 1: Leber
Jenssen, C., Pietsch, C., Gottschalk, U., Barreiros, A. M., Teufel, A., Cui, X., & Dietrich, C. F. (2015) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0034-1398949 · Cited by 5
The Past, Present, and Future of Noninvasive Test in Chronic Liver Diseases
Chee, D., Ng, C. H., Chan, K. E., Huang, D. Q., Teng, M. L. P., & Muthiah, M. D. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.12.001 · Cited by 4
The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease
Pennisi, G., Celsa, C., Giammanco, A., Spatola, F., & Petta, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200521133307 · Cited by 4
Metadata
- Authors
- Angulo, P., Bugianesi, E., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Barrera, F., Haflidadottir, S., Day, C. P., & George, J.
- Affiliations
- University of Kentucky HealthCare (US)
- University of Turin (IT)
- National University Hospital of Iceland (IS)
- Siriraj Hospital (TH)
- Gartnavel General Hospital (GB)
- Newcastle University (GB)
- The University of Sydney (AU)
- Corresponding author
- Angulo, Paul
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 145
- Issue
- 4
- Pages
- 782-789.e4
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC3931256
- OpenAlex
- W2129639561
- Cited by
- 502
- References
- 32
- Citations by year
- 2026: 7 · 2025: 29 · 2024: 31 · 2023: 32 · 2022: 46 · 2021: 60 · 2020: 49 · 2019: 40 · 2018: 39 · 2017: 35 · 2016: 36 · 2015: 49 · 2014: 45 · 2013: 4
- FWCI
- 32.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- National Institutes of Health (R01 DK82426)
- Seventh Framework Programme (HEALTH-F2-2009-241762)
- National Health and Medical Research Council (1049857, 632630)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, NAFLD fibrosis score, FIB-4, BARD score, liver complications, mortality, liver transplantation, disease progression, prognosis, liver fibrosis, risk stratification, prognostic accuracy
- MeSH terms
- Adult, Fatty Liver, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Cohort Studies, Kaplan-Meier Estimate, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
